Synchronous lung adenocarcinoma in situ and type B2-B3 thymoma in a frozen hemithorax: a case report and multidisciplinary approach - Report - MDSpire

Synchronous lung adenocarcinoma in situ and type B2-B3 thymoma in a frozen hemithorax: a case report and multidisciplinary approach

  • By

  • Chenglin Fan

  • Gaoyuan Sang

  • Ziyi Liang

  • Jialin Yu

  • Sixuan Song

  • Jingjun Zhu

  • Zhengzhe Xu

  • May 15, 2026

Share

Concurrent lung adenocarcinoma in situ and type B2-B3 thymoma: a case study

Overview

This case study presents a 73-year-old woman diagnosed with synchronous lung adenocarcinoma in situ and type B2-B3 thymoma. The report emphasizes the diagnostic challenges posed by hypermetabolic lesions on PET/CT and the successful management through a multidisciplinary approach.

Background

Incorporate statistics or references to emphasize the rarity of synchronous lung cancer and thymoma.

Data Highlights

No numerical data or trial data presented in the article.

Key Findings

  • A 73-year-old female presented with a hypermetabolic right upper lobe nodule and anterior mediastinal mass.
  • Initial pathology revealed adenocarcinoma in situ (AIS) obscured by organizing pneumonia.
  • Final pathology confirmed synchronous B2-B3 thymoma alongside AIS.
  • Uniportal video-assisted thoracoscopic surgery (VATS) was successfully performed despite extensive pleural adhesions.
  • The patient had an uneventful postoperative course and was discharged on postoperative day 6.

Clinical Implications

Elaborate on how this case may influence future clinical practices or research directions.

Conclusion

The report highlights the diagnostic challenges of synchronous thoracic neoplasms and validates the effectiveness of uniportal VATS in high-risk patients. Continued vigilance in imaging interpretation and management strategies is essential.

Related Resources & Content

  1. Frontiers in Medicine, 2026 -- Case Report: A seventy-year-stable chest wall bronchogenic cyst with sudden enlargement: coincidence or connection with a concurrent thymic carcinoma?
  2. Frontiers in Oncology, 2026 -- Sequential multimodal management for recurrent pulmonary NUT carcinoma: a case report
  3. Frontiers in Surgery, 2026 -- Giant Adenoid Cystic Carcinoma in the Subglottic Region: A Case Study
  4. Updates in Surgery, 2025 -- Expression of programmed death-ligand 1 in thymomas following surgical resection
  5. NCCN Guidelines® Insights, 2025 -- Non-Small Cell Lung Cancer, Version 7.2025
  6. EANM consensus document, 2024 -- The use of [18F]FDG PET/CT in fever and inflammation of unknown origin
  7. Lung Decortication - StatPearls, NCBI Bookshelf
  8. NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 7.2025 - PubMed
  9. EANM consensus document on the use of [18F]FDG PET/CT in fever and inflammation of unknown origin | European Journal of Nuclear Medicine and Molecular Imaging | Springer Nature Link
  10. Lung Decortication - StatPearls - NCBI Bookshelf

Original Source(s)

Synchronous lung adenocarcinoma in situ and type B2-B3 thymoma in a frozen hemithorax: a case report and multidisciplinary approach

  • by Chenglin Fan, Gaoyuan Sang, Ziyi Liang, Jialin Yu, Sixuan Song, Jingjun Zhu, Zhengzhe Xu

  • May 15, 2026

Related Content

Does the Timing of Immunotherapy Administration Affect Outcomes in Advanced Cancers?

A systematic review and meta-analysis found that early time-of-day immunotherapy was associated with improved survival outcomes in patients with advanced cancers, with the association appearing to be ...

Combination Enzalutamide and Radium-223 Extends Overall Survival in Bone-Dominant mCRPC

In the final analysis of the phase III EORTC 1333/PEACE-3 trial, with a median follow-up of 58 months, the addition of radium-223 to the androgen receptor inhibitor enzalutamide significantly prolonge...

Lack of Research in Understanding the Global Population of Childhood Cancer Survivors Leads to Gaps in Care and Cures

Each year, globally, about 400,000 children and adolescents aged between 0 and 19 years are diagnosed with cancer; over 100,000 die from the disease, with most of those cases, over 80%, and deaths occ...